<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hvivo Plc — News on 6ix</title>
<link>https://6ix.com/company/hvivo-plc</link>
<description>Latest news and press releases for Hvivo Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hvivo-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e70778dffbe2df128d64.webp</url>
<title>Hvivo Plc</title>
<link>https://6ix.com/company/hvivo-plc</link>
</image>
<item>
<title>HCT contract signed with ILiAD Biotechnologies</title>
<link>https://6ix.com/company/hvivo-plc/news/hct-contract-signed-with-iliad-biotechnologies</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/hct-contract-signed-with-iliad-biotechnologies</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>hVIVO plc has secured a contract to conduct the world's first pivotal Phase III human challenge trial for ILiAD Biotechnologies' whooping cough vaccine candidate, BPZE1. This trial, hVIVO's largest to date, will involve over 500 participants and is expected to generate significant revenue, with the majority recognised in 2026 and 2027, contributing strongly to near and mid-term financial performance. The study will assess BPZE1's efficacy against the current standard of care and is crucial for I</description>
</item>
<item>
<title>Final Results 2025</title>
<link>https://6ix.com/company/hvivo-plc/news/final-results-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/final-results-2025-2</guid>
<pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
<description>hVIVO plc reported a decrease in revenue to £46.8 million for the year ended December 31, 2025, down from £62.7 million in 2024, alongside a significant drop in adjusted EBITDA to £1.4 million from £16.4 million, resulting in a basic adjusted earnings per share of (0.41)p compared to 1.69p in the prior year. The company's cash reserves also reduced to £14.3 million from £44.2 million, while the contracted orderbook stood at £30 million, down from a restated £43.5 million. These results reflect t</description>
</item>
<item>
<title>hVIVO launches unified brand identity</title>
<link>https://6ix.com/company/hvivo-plc/news/hvivo-launches-unified-brand-identity</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/hvivo-launches-unified-brand-identity</guid>
<pubDate>Tue, 14 Apr 2026 06:01:00 GMT</pubDate>
<description>hVIVO plc has launched a new unified brand identity to reflect its strategic transformation into an integrated clinical development partner, moving from a specialist provider to an end-to-end drug development partner. This rebrand signifies the completion of the Group's integration of Venn Life Sciences, CRS, and Cryostore, now operating under the single hVIVO brand across four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories. This unified platform </description>
</item>
<item>
<title>Issue of Equity and Total Voting Rights</title>
<link>https://6ix.com/company/hvivo-plc/news/issue-of-equity-and-total-voting-rights-68</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/issue-of-equity-and-total-voting-rights-68</guid>
<pubDate>Mon, 23 Feb 2026 07:00:00 GMT</pubDate>
<description>hVIVO plc has announced the issuance of 1,386,991 new Ordinary Shares as the first tranche of equity consideration for the acquisition of Cryostore, with a further tranche of up to 1,386,991 shares to be issued on the second anniversary, subject to continued employment. These First Consideration Shares are expected to be admitted to trading on the AIM Market of the London Stock Exchange on 26 February 2026, bringing the total number of Ordinary Shares in issue to 688,401,079.
Dis</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/hvivo-plc/news/trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/trading-update</guid>
<pubDate>Thu, 29 Jan 2026 12:00:00 GMT</pubDate>
<description>hVIVO plc expects to report FY25 revenue of approximately £46.7 million, in line with expectations, and a positive low single-digit adjusted EBITDA margin, exceeding previous guidance. Despite a decrease from £62.7 million in 2024, the company's cash position stands at approximately £14.3 million as of December 31, 2025, with no debt. These results are attributed to stronger Q4 operational delivery and contractual protections. The integration of strategic acquisitions, CRS Mannheim & Kiel and Cr</description>
</item>
<item>
<title>Notice of Trading Update</title>
<link>https://6ix.com/company/hvivo-plc/news/notice-of-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/notice-of-trading-update</guid>
<pubDate>Tue, 27 Jan 2026 12:00:00 GMT</pubDate>
<description>hVIVO plc has announced that it will release its trading update for the year ended 31 December 2025 on Thursday, 29 January 2026. The company's Chief Executive Officer and Chief Financial Officer will present the update via the Investor Meet Company platform at 6pm on the same day, offering existing and potential shareholders the opportunity to ask questions both before and during the event.
Disclaimer*</description>
</item>
<item>
<title>Appointment of Non-Executive Director</title>
<link>https://6ix.com/company/hvivo-plc/news/appointment-of-non-executive-director-2</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/appointment-of-non-executive-director-2</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>hVIVO plc has appointed Richard Cotton as an Independent Non-Executive Director, effective immediately, who will also chair the Audit Committee. Cotton brings extensive financial and life sciences board-level experience, having previously served as CFO for Dechra Pharmaceuticals plc and Consort Medical plc. His appointment is expected to enhance the Board's capabilities as the company focuses on strategic opportunities and delivering shareholder value.
Disclaimer*</description>
</item>
<item>
<title>CEO & CFO Share Purchase</title>
<link>https://6ix.com/company/hvivo-plc/news/ceo-and-cfo-share-purchase</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/ceo-and-cfo-share-purchase</guid>
<pubDate>Mon, 15 Dec 2025 19:47:00 GMT</pubDate>
<description>hVIVO plc announced that on December 15, 2025, Chief Executive Officer Yamin 'Mo' Khan purchased 3,310,405 ordinary shares at 6.04 pence each, increasing his holding to 8,322,008 shares representing 1.21% of issued share capital. Additionally, Chief Financial Officer Stephen Pinkerton acquired 520,000 ordinary shares at 5.5 pence each, bringing his resultant holding, including shares held by his wife, to 1,270,596 shares or 0.19% of the issued share capital. These transactions, considered inside</description>
</item>
<item>
<title>MSD to acquire Cidara</title>
<link>https://6ix.com/company/hvivo-plc/news/msd-to-acquire-cidara</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/msd-to-acquire-cidara</guid>
<pubDate>Thu, 27 Nov 2025 12:00:00 GMT</pubDate>
<description>hVIVO plc announced that its client, Cidara Therapeutics, Inc., has entered into an agreement for MSD to acquire Cidara for approximately $9.2 billion, a transaction underscoring hVIVO's role in accelerating drug development. hVIVO provided critical data for Cidara's lead candidate, CD388, an antiviral agent, through a human challenge study in 2023 and a large-scale Phase IIb field study over the 2024/2025 flu season, where hVIVO enrolled 817 participants, the highest number globally. hVIVO also</description>
</item>
<item>
<title>>£5 million CRS contracts signed</title>
<link>https://6ix.com/company/hvivo-plc/news/greaterpound5-million-crs-contracts-signed</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/greaterpound5-million-crs-contracts-signed</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>hVIVO plc announced that its German subsidiary, CRS, has secured new contracts exceeding £5 million since September, with two returning mid-sized German pharmaceutical clients contributing significantly. These early-phase clinical trial service contracts, spanning multiple therapeutic areas including cardiometabolic, dermatology, infectious disease, renal impairment, and cancer, are scheduled to commence this year and in the first half of 2026, with the majority of revenue expected in 2026. The </description>
</item>
<item>
<title>Positive data from novel human challenge models</title>
<link>https://6ix.com/company/hvivo-plc/news/positive-data-from-novel-human-challenge-models</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/positive-data-from-novel-human-challenge-models</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>hVIVO plc announced positive data from newly developed human challenge models presented at the ESWI and World Vaccine Congress Europe conferences. The company showcased its world-first contemporary-strain hMPV challenge model, its first commercially available Omicron BA5 SARS-CoV-2 challenge model, and a robust RSV B challenge model, all demonstrating acceptable safety profiles and readiness for vaccine and antiviral trials. These developments enhance hVIVO's capability to accelerate novel thera</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/hvivo-plc/news/holdings-in-company-3</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/holdings-in-company-3</guid>
<pubDate>Thu, 06 Nov 2025 22:05:00 GMT</pubDate>
<description>Rathbones Investment Management Ltd has notified hVIVO PLC of a disposal of voting rights, crossing a major holding threshold on November 5, 2025. The investment firm's total voting rights in hVIVO PLC now stand at 10.9966%, representing 75,548,245 shares. This marks a decrease from its previously notified position of 11.9621%. This reduction in a significant institutional holding could be perceived negatively by the market, potentially impacting hVIVO PLC's share price.
Disclaim</description>
</item>
<item>
<title>Presentation at Jefferies Healthcare Conference</title>
<link>https://6ix.com/company/hvivo-plc/news/presentation-at-jefferies-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/presentation-at-jefferies-healthcare-conference</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>hVIVO plc will present at the Jefferies Global Healthcare Conference in London on November 20, 2025, at 12:30 pm GMT. The conference, held from November 17-20, is expected to host over 700 healthcare companies and 3,600 attendees, facilitating 10,000 investor and business-to-business meetings. The presentation material will be available on the company's website shortly after the event. No new material information will be disclosed during the presentation.
Disclaimer*</description>
</item>
<item>
<title>Interim results</title>
<link>https://6ix.com/company/hvivo-plc/news/interim-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/interim-results-1</guid>
<pubDate>Tue, 23 Sep 2025 11:00:00 GMT</pubDate>
<description>hVIVO plc announced its unaudited interim results for the six months ended 30 June 2025. The company reported revenue of £24.2 million, which includes £5.2 million from CRS and £0.3 million from Cryostore. The EBITDA pre-exceptionals was £3.0 million, with an EBITDA margin of 12.5%. Basic adjusted earnings per share were 0.29p. As of 30 June 2025, hVIVO had cash reserves of £23.3 million and a weighted contracted orderbook of £40 million. Exceptional items, comprising acquisition-related and res</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/hvivo-plc/news/notice-of-results</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/notice-of-results</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>hVIVO plc will release its interim results for the six months ended June 30, 2025, on Tuesday, September 23, 2025. An analyst briefing will occur on the same day at 10:30 am BST. Furthermore, a live investor presentation regarding the interim results, led by the Chief Executive Officer and Chief Financial Officer, is scheduled for 6:00 pm BST on the Investor Meet Company platform.
Disclaimer*</description>
</item>
<item>
<title>Appointment of Non-Executive Chair</title>
<link>https://6ix.com/company/hvivo-plc/news/appointment-of-non-executive-chair</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/appointment-of-non-executive-chair</guid>
<pubDate>Mon, 01 Sep 2025 11:00:00 GMT</pubDate>
<description>hVIVO plc announced that Shaun Chilton has joined the Board of Directors as Non-Executive Chair, effective today, September 1, 2025. Chilton, aged 57, brings over 30 years of experience, including his previous role as Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in over 100 countries. He currently holds Non-Executive Chair positions at Avacta Group plc and Kintiga Limited, and is an Independent Supervisory Board Member of Product Life Group. Chi</description>
</item>
<item>
<title>Proposed appointment of Chair</title>
<link>https://6ix.com/company/hvivo-plc/news/proposed-appointment-of-chair</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/proposed-appointment-of-chair</guid>
<pubDate>Tue, 29 Jul 2025 11:00:00 GMT</pubDate>
<description>Proposed appointment of Chair.</description>
</item>
<item>
<title>H1 Trading update</title>
<link>https://6ix.com/company/hvivo-plc/news/h1-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/h1-trading-update</guid>
<pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
<description>H1 Trading update.</description>
</item>
<item>
<title>Directorate Change</title>
<link>https://6ix.com/company/hvivo-plc/news/directorate-change-1</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/directorate-change-1</guid>
<pubDate>Fri, 18 Jul 2025 11:00:00 GMT</pubDate>
<description>Directorate Change.</description>
</item>
<item>
<title>Positive results from client Phase 2b field study</title>
<link>https://6ix.com/company/hvivo-plc/news/positive-results-from-client-phase-2b-field-study</link>
<guid isPermaLink="true">https://6ix.com/company/hvivo-plc/news/positive-results-from-client-phase-2b-field-study</guid>
<pubDate>Mon, 30 Jun 2025 11:00:00 GMT</pubDate>
<description>Positive results from client Phase 2b field study.</description>
</item>
</channel>
</rss>